| 1 |
Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis[J]. Nat Rev Dis Primers, 2018, 4 (1): 38.
|
| 2 |
Gertz MA. Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment[J]. Am J Hematol, 2020, 95 (7): 848-860.
|
| 3 |
Dispenzieri A, Merlini G. Immunoglobulin light chain systemic amyloidosis[J]. Cancer Treat Res, 2016 (169): 273-318.
|
| 4 |
Andrei M, Wang JC. Cutaneous light chain amyloidosis with multiple myeloma: a concise review[J]. Hematol Oncol Stem Cell Ther, 2019, 12 (2): 71-81.
|
| 5 |
Blancas-Mejía LM, Ramirez-Alvarado M. Systemic amyloidoses[J]. Annu Rev Biochem, 2013 (82): 745-774.
|
| 6 |
Fotiou D, Dimopoulos MA, Kastritis E. Systemic AL amyloidosis: current approaches to diagnosis and management[J]. Hemasphere, 2020, 4 (4): e454.
|
| 7 |
段金凤，简银花，蔡巍.血栓性血小板减少性紫癜伴Ⅲ。房室传导阻滞一例[J/CD].中华危重症医学杂志（电子版），2013，6（4）：247-249.
|
| 8 |
Wanat KA, Kim B, Rosenbach M. Multisystem diseases affecting the skin and eye[J]. Clin Dermatol, 2016, 34 (2): 214-241.
|
| 9 |
Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium[J]. Adv Ther, 2015, 32(10): 920-928.
|
| 10 |
Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis[J]. Blood, 2012, 119 (19): 4391-4394.
|